人ProIGF-IE(71 - 86)抗血清通过用衍生自与白喉类毒素连接的人ProIGF-IE的E结构域的16个氨基酸的肽免疫兔来制备。 肽序列位于成熟IGF-I的C末端切割位点的紧下游,因此,抗血清识别所有来源于人igf-1基因可变剪接的ProIGF-I E蛋白。 它不识别成熟的IGF-I或IGF-II。 由于igf-1基因的选择性剪接,它可能在非人灵长类动物、兔和豚鼠中识别ProIGF-I E蛋白,但在其它物种中不识别。 Human ProIGF-I E (71-86) antiserum was prepared by immunising rabbits with a 16 amino acid peptide derived from the E domain of human ProIGF-I E linked to diphtheria toxoid. The peptide sequence is located immediately downstream of the cleavage site at the C terminus of mature IGF-I and as a consequence, the antiserum recognises all ProIGF-I E proteins derived from alternative splicing of the human igf-1 gene. It does not recognise mature IGF-I or IGF-II. It is likely to recognise ProIGF-I E proteins in non-human primates, rabbits and guinea-pigs but not other species due to alternative splicing of the igf-1 gene.
GroPep Bioreagents公司总部位于澳大利亚,成立于1990年,致力于向广大科研院所、生物技术及制药公司开发、生产和销售细胞培养级的活性生长因子(主要集中在胰岛素样生长因子(IGF)领域)、抗体及相关蛋白试剂,现有产品超过100多个,同时在世界范围内均设有分销商。公司在分子生物领域、发酵学及重组蛋白和单抗制备方面具有丰富的经验,在制造工艺方面,拥有大量专利技术,GroPep目前已通过AS/NZS ISO 9001:2016质量管理体系认证。